Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_3
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Other(3)

Detailed Status

unknown3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

unknown375%
not_yet_recruiting125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety

NCT07356791
unknownphase_1

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

NCT05928962
unknownphase_4

Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment

NCT05113290
unknownphase_3

TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

NCT01869088

Clinical Trials (4)

Showing 4 of 4 trials
NCT07356791Phase 2

Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety

Not Yet Recruiting
NCT05928962Phase 1

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Unknown
NCT05113290Phase 4

Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment

Unknown
NCT01869088Phase 3

TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4